Bayer receives approval for darolutamide in Japan (for specialized target groups only)
Marketing authorization granted for the treatment of men with non-metastatic castration-resistant prostate cancer
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Japan Health | Marketing | Pharmaceuticals | Prostate Cancer